C57BL/6JCya-Spred1em1flox/Cya
Common Name:
Spred1-flox
Product ID:
S-CKO-17852
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Spred1-flox
Strain ID
CKOCMP-114715-Spred1-B6J-VB
Gene Name
Product ID
S-CKO-17852
Gene Alias
5730461F13Rik
Background
C57BL/6JCya
NCBI ID
Modification
Conditional knockout
Chromosome
2
Phenotype
Document
Application
--
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Spred1em1flox/Cya mice (Catalog S-CKO-17852) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000028829
NCBI RefSeq
NM_033524
Target Region
Exon 2
Size of Effective Region
~1.2 kb
Detailed Document
Overview of Gene Research
Spred1, short for Sprouty-related, EVH1 domain-containing protein 1, is a negative regulator of the RAS-MAPK signaling pathway [5,6,7]. It belongs to the Sprouty related protein family and is crucial for normal cellular growth and development, playing a role in downregulating this key signaling cascade that is involved in numerous biological processes such as cell proliferation, differentiation, and survival [5,6,7]. Genetic models, like knockout (KO) mouse models, have been instrumental in studying its function.
In chronic myelogenous leukemia (CML), Spred1 knockout in SCLtTA/BCR-ABL CML mice, whether global or restricted to hematopoietic cells (HSCs) or endothelial cells (ECs), led to the transformation of chronic phase CML into accelerated phase/blast crisis CML. Spred1 KO increased miR-126 in LSKs, expanding leukemic stem cells likely via hyperactivation of the MAPK/ERK pathway, enhancing Bcl-2-dependent oxidative phosphorylation, and driving the transformation [1]. In melanoma, SPRED1 inactivation in human melanoma cell lines and primary zebrafish melanoma conferred resistance to BRAFV600E inhibition by re-activating MAPK activity, and biallelic deletion was seen in a patient with acquired resistance to MAPK-targeted therapy [2]. In acute myeloid leukemia (AML), in vitro experiments using THP-1 cells showed that demethylation of SPRED1 could inhibit cell proliferation and promote differentiation and apoptosis, possibly through the ERK pathway [3]. Also, in AML, decreased SPRED1 expression was associated with lower 2-year progression-free and event-free survival rates in non-acute promyelocytic leukemia patients, and ectopic overexpression of SPRED1 in THP-1 cells led to decreased ERK phosphorylation, apoptosis induction, and reduced cell proliferation [4].
In summary, Spred1 is essential for regulating the RAS-MAPK signaling pathway, which impacts various biological processes. Model-based research, especially KO mouse models, has revealed its significant roles in diseases such as CML, melanoma, and AML. Understanding Spred1's functions provides insights into disease mechanisms and potential therapeutic targets for these malignancies.
References:
1. Qiao, Junjing, Liang, Chen, Zhao, Dandan, Zhang, Bin Amber, Marcucci, Guido. 2021. Spred1 deficit promotes treatment resistance and transformation of chronic phase CML. In Leukemia, 36, 492-506. doi:10.1038/s41375-021-01423-x. https://pubmed.ncbi.nlm.nih.gov/34564700/
2. Ablain, Julien, Liu, Sixue, Moriceau, Gatien, Lo, Roger S, Zon, Leonard I. . SPRED1 deletion confers resistance to MAPK inhibition in melanoma. In The Journal of experimental medicine, 218, . doi:10.1084/jem.20201097. https://pubmed.ncbi.nlm.nih.gov/33306107/
3. Su, Nan, Wang, Yujiao, Lu, Xianglan, Li, Yan, Zhang, Rui. 2022. Methylation of SPRED1: A New Target in Acute Myeloid Leukemia. In Frontiers in oncology, 12, 854192. doi:10.3389/fonc.2022.854192. https://pubmed.ncbi.nlm.nih.gov/35359401/
4. Zhang, Rui, Zhang, Yan, Lu, Xianglan, Yan, Xiaojing, Li, Yan. 2020. SPRED1 Is Downregulated and a Prognostic Biomarker in Adult Acute Myeloid Leukemia. In Frontiers in oncology, 10, 204. doi:10.3389/fonc.2020.00204. https://pubmed.ncbi.nlm.nih.gov/32175275/
5. Brems, Hilde, Pasmant, Eric, Van Minkelen, Rick, Legius, Eric, Messiaen, Ludwine. 2012. Review and update of SPRED1 mutations causing Legius syndrome. In Human mutation, 33, 1538-46. doi:10.1002/humu.22152. https://pubmed.ncbi.nlm.nih.gov/22753041/
6. Brems, Hilde, Legius, Eric. 2013. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1. In The Keio journal of medicine, 62, 107-12. doi:. https://pubmed.ncbi.nlm.nih.gov/24334617/
7. Chelleri, Cristina, Brolatti, Noemi, De Marco, Patrizia, Zara, Federico, Scala, Marcello. 2024. Novel causative variants in Legius syndrome: SPRED1 Genotype spectrum expansion. In American journal of medical genetics. Part A, 194, e63824. doi:10.1002/ajmg.a.63824. https://pubmed.ncbi.nlm.nih.gov/39031930/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen